Body Protection Compound · Versatile Regenerative Research Peptide

BPC-157

Body Protection Compound-157 · Pentadecapeptide

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Preclinical research data suggests potential activity across a range of tissue types, including tendon, ligament, muscle, gut, and vascular tissue. Research has investigated its potential role in angiogenesis, inflammation modulation, and tissue repair. Clinical human data remains limited. This compound is investigational, and its compounding availability is subject to current FDA regulations.

Proposed research mechanisms: Potential upregulation of growth hormone receptors in tendon fibroblasts · Possible promotion of angiogenic signaling · Anti-inflammatory activity in multiple models. Evidence primarily preclinical.

Typical Administration

Subcutaneous injection (systemic) or oral formulation (GI-specific) · Daily

Thymosin Beta-4 Analogue · Systemic Repair Research

TB-500

Thymosin Beta-4 Active Fragment · Systemic Regenerative Peptide

TB-500 is the active fragment of Thymosin Beta-4, a protein involved in actin regulation, cell migration, and wound healing biology. Research data suggests potential for tissue repair support, particularly in musculoskeletal and vascular contexts. Often used in combination with BPC-157 in clinical protocols. Evidence is primarily preclinical, with limited human data.

‍

• ⚠ INVESTIGATIONAL. Not FDA-approved. Subject to current FDA compounding regulations. Availability may change. Full regulatory disclosure and informed consent required.

Typical Administration

Subcutaneous injection · Loading phase 2x weekly, maintenance weekly

Copper Tripeptide · Aesthetic & Tissue Research

GHK-Cu

Copper Tripeptide-1 · Arbour Longevity Glow Protocol

GHK-Cu is a naturally occurring copper-binding tripeptide studied for its potential roles in collagen synthesis stimulation, tissue remodeling, and antioxidant activity. At Arbour Longevity, it anchors the Glow Protocol, used systemically and topically in conjunction with aesthetic PRP recovery support and skin health programs. Research suggests a range of potential regenerative and anti-aging mechanisms, primarily in vitro and preclinical models.

• Investigational compound. Compounding availability subject to current FDA regulations. Full disclosure at consultation.

Typical Administration

Subcutaneous injection (systemic) or topical application · Combined protocols available

Combination Protocol · Research-Based Regenerative Stack

BPC-157 + TB-500 Stack

Combined Regenerative Protocol · Subject to Compound Availability

BPC-157 and TB-500 are frequently combined in clinical protocols for their complementary proposed mechanisms. This combination is often considered alongside PRP joint therapy at Arbour Longevity, where peptides may optimize the biological environment while PRP delivers concentrated growth factors directly to the target tissue. All compound availability is subject to current FDA regulations, confirmed at consultation.

• Both compounds investigational. Availability subject to current FDA compounding regulations. Combination protocol reviewed and consented individually.